scholarly journals Prognosis of Lymphangitic Tumor Spread Detected on Chest CT Scan During Staging Evaluation in Patients with Non-Small Cell Lung Cancer

2020 ◽  
Author(s):  
Y. Im ◽  
B.-H. Jeong ◽  
K. Lee ◽  
H. Kim ◽  
O.J. Kwon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Ct Scan ◽  
Cell Lung Cancer ◽  
Chest Ct ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Spread ◽  
Chest Ct Scan

scholarly journals Prognosis of P-N2 Non-small Cell Lung Cancer with Special Emphasis on the Significance ofa Chest CT Diagnosis of Metastasis to Mediastinal Lymph Nodes.

Haigan ◽  
1993 ◽  
Vol 33 (7) ◽  
pp. 1031-1036
Author(s):  
Masao Ichiki ◽  
Masanori Sakurai ◽  
Izumi Hayashi ◽  
Yukitoshi Sato ◽  
Sakae Okumura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Nodes ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Chest Ct ◽  
Small Cell ◽  
Mediastinal Lymph Nodes ◽  
Ct Diagnosis ◽  
Small Cell Lung

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy

2020 ◽  
pp. 829-840 ◽  
Author(s):  
Roberto Ferrara ◽  
Laura Mezquita ◽  
Matthieu Texier ◽  
Jihene Lahmar ◽  
Clarisse Audigier-Valette ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Ct Scan ◽  
Cell Lung Cancer ◽  
Group Performance ◽  
Single Agent ◽  
Small Cell ◽  
Small Cell Lung ◽  
Fast Progression ◽  
Hyperprogressive Disease

PURPOSE Hyperprogressive disease (HPD), fast progression (FP), and early death (ED) have been described in 13.8%, 4.7%, and 5.6% and in 5.1%, 2.8%, and 6.8%, respectively, of patients with non–small-cell lung cancer (NSCLC) treated with single-agent programmed cell death ligand 1 inhibitors (ICI) or chemotherapy, respectively. Whether FP/ED and HPD represent overlapping patterns is unknown. PATIENTS AND METHODS FP, ED, and HPD were retrospectively assessed in patients with NSCLC treated with single-agent ICI or chemotherapy. Eligibility required 2 computed tomography (CT) scans before and 1 CT scan during treatment. (1) HPD, (2) FP, (3) ED were defined as (1) RECIST version 1.1 progression at first CT scan and tumor growth rate variation per month > 50%, (2) ≥ 50% increase in the sum of the longest diameters of target lesions within 6 weeks from baseline, and (3) death as a result of radiologic progression within 12 weeks from baseline CT scan, respectively. RESULTS Of 406 ICI-treated NSCLC, 56 patients (13.8%), 9 patients (2.2%), and 36 patients (8.8%) were HPD, FP, and ED, respectively. Eight (14.2%) and 20 (35.7%) of 56 patients with HPD were also FP and ED. ED significantly correlated with baseline Eastern Cooperative Oncology Group performance status ≥ 2 compared with HPD (33% v 13%, P = .02). Overall survival was significantly longer for HPD (3.4 months [95% CI, 2.7 to 4.0 months]) compared with FP (0.7 months [95% CI, 0.6 to 0.8 months]); HR, 0.18 [95% CI, 0.08 to 0.42]; P < .0001) and ED (1.4 months [95% CI, 1.3 to 1.6 months]); HR, 0.19 [95% CI, 0.11 to 0.34]); P < .0001), whereas it did not differ between FP and ED (HR, 1.3 [95% CI, 0.56 to 3.0]; P = .55). Of 59 patients with NSCLC treated with single-agent chemotherapy, the HPD, FP, and ED rates were 5.1%, 1.7%, and 6.7%, respectively. CONCLUSION FP, ED, and HPD represent distinct progression patterns with limited overlap and different survival outcomes.

Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT

2016 ◽  
Vol 24 (11) ◽  
pp. 4721-4726 ◽  
Author(s):  
Eun Young Kim ◽  
Young Saing Kim ◽  
Inkeun Park ◽  
Hee Kyung Ahn ◽  
Eun Kyung Cho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Chest Ct ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Routine Chest

Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: Evaluation of tumor tissue and response at a single center.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20664-e20664
Author(s):  
Lucia Nogova ◽  
Florian Malchers ◽  
Elisabeth Bitter ◽  
Sebastian Yves Friedrich Michels ◽  
Rieke Nila Fischer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Ct Scan ◽  
Cell Lung Cancer ◽  
Phase I Study ◽  
Tumor Tissue ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pik3ca Mutations

e20664 Background: Fibroblast growth factor receptor 1 ( FGFR1) amplification in squamous cell non-small cell lung cancer (sqNSCLC) has been described as potential oncogenic and targetable driver in cell lines and murine models. However, a phase I study evaluating FGFR 1-3 inhibitor BGJ398 showed moderate response rate of 11% in FGFR1amplified sgNSCLC treated with dose ≥ 100mg. To identify underlying mechanisms of resistance, we analyzed tumor tissues of selected patients. Methods: Within the phase I BGJ398 study, patients (pts) with FGFR1amplified sqNSCLC were treated orally with escalating dose (5 to 150mg) of BGJ398 once daily (QD) or 50mg twice a day. In the expansion phase, pts received BGJ398 either continuously QD or on a 3-weeks on/1-week off schedule. CT scans for response were performed every 8 weeks. Available tumor tissue of pts treated with BGJ398 at our center was analyzed using hybrid capture–based massively parallel sequencing (CAGE). Results: Twenty-one pts with FGFR1 amplified sqNSCLC were treated with ≥ 100mg BGJ398 at our site. As best response, 3 pts showed partial response (PR), 7 pts stable disease (SD) and 7 pts progressive disease (PD). Two pts withdrew their consents and 2 pts died ahead of first CT scan: one due to infection and one due to sudden death. We performed CAGE covering 256 genes on 9 patients: on 3 pts with PR, 2 pts with SD, 2 pts with PD and 2 pts who died before first CT scan. All analyzed patients harbored mutations in TP53. Additionally, we detected two CDKN2A (one patient with PR and one patient who died before first CT) and three MLL2 stop codon and frame shift mutations (two patients with SD and one patient with PD). Of interest, we identified three patients with two canonical (one patient with SD and one patient who died before first CT) and one non-canonical mutations in PIK3CA(one patient with SD). Conclusions: In our analysis, MLL2 and PIK3CA mutations seem to have a negative impact on response in FGFR1 amplified pts treated with BGJ398. Further analysis with higher patient number is needed to identify the role of MLL2 and PIK3CA mutations in FGFR1 amplified sqNSCLC. Clinical trial information: NCT01004224.

scholarly journals Morphological Subtypes of Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: Prognostic Heterogeneity and Its Underlying Mechanism

2021 ◽  
Vol 11 ◽  
Author(s):  
Huikang Xie ◽  
Hang Su ◽  
Erjia Zhu ◽  
Chang Gu ◽  
Shengnan Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prospective Study ◽  
Small Cell Lung Cancer ◽  
Single Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Spread ◽  
Specimen Handling ◽  
Spread Through Air Spaces

BackgroundTumor spread through air spaces (STAS) has three morphologic subtypes: single cells, micropapillary clusters, and solid nests. However, whether their respective clinical significance is similar remains unclear.MethodsWe retrospectively reviewed 803 patients with resected non-small cell lung cancer (NSCLC) from January to December 2009. Recurrence-free survival (RFS) and overall survival (OS) were compared among patients stratified by STAS subtypes. We also performed a prospective study of NSCLC resection specimens to evaluate the influence of a prosecting knife on the presence of STAS subtypes during specimen handling (83 cases).ResultsSTAS was found in 370 NSCLCs (46%), including 47 single cell STAS (13%), 187 micropapillary cluster STAS (50%), and 136 solid nest STAS (37%). STAS-negative patients had significantly better survival than patients with micropapillary cluster STAS (RFS: P &lt; 0.001; OS: P &lt; 0.001) and solid nest STAS (RFS: P &lt; 0.001; OS: P &lt; 0.001), but similar survival compared with those with single cell STAS (RFS: P = 0.995; OS: P = 0.71). Multivariate analysis revealed micropapillary cluster (RFS: P &lt; 0.001; OS: P &lt; 0.001) and solid nest STAS (RFS: P = 0.001; OS: P = 0.003) to be an independent prognostic indicator, but not for single cell STAS (RFS: P = 0.989; OS: P = 0.68). Similar results were obtained in subgroup analysis of patients with adenocarcinoma. The prospective study of NSCLC specimens suggested that 18 cases were considered as STAS false-positive, and most were singe cell pattern (13/18, 72%).ConclusionsSingle cell STAS was the common morphologic type of artifacts produced by a prosecting knife. A precise protocol of surgical specimen handling is required to minimize artifacts as much as possible.

scholarly journals Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines

Cancers ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 114 ◽  
Author(s):  
Barbara Rath ◽  
Lukas Klameth ◽  
Adelina Plangger ◽  
Maximilian Hochmair ◽  
Ernst Ulsperger ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Vascular Tissue ◽  
Proteolytic Enzymes ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Spread

Small cell lung cancer (SCLC) is an aggressive type of lung cancer which disseminates vigorously and has a dismal prognosis. Metastasis of SCLC is linked to an extremely high number of circulating tumor cells (CTCs), which form chemoresistant spheroids, termed tumorospheres. Intravasation and extravasation during tumor spread requires the activity of a number of proteases to disintegrate the stroma and vascular tissue. Generation of several permanent SCLC CTC lines allowed us to screen for the expression of 35 proteases using Western blot arrays. Cell culture supernatants of two CTC lines, namely BHGc7 and 10, were analyzed for secreted proteases, including matrix metalloproteinases (MMPs), ADAM/TS, cathepsins, kallikreins, and others, and compared to proteases expressed by SCLC cell lines (GLC14, GLC16, NCI-H526 and SCLC26A). In contrast to NCI-H526 and SCLC26A, MMP-9 was highly expressed in the two CTC lines and in GLC16 derived of a relapse. Furthermore, cathepsins (S, V, X/Z/P, A and D) were highly expressed in the CTC lines, whereas ADAM/TS and kallikreins were not detectable. In conclusion, SCLC CTCs express MMP-9 and a range of cathepsins for proteolysis and, aside from tissue degradation, these enzymes are involved in cell signaling, survival, and the chemoresistance of tumor cells.

Sign in / Sign up

Export Citation Format

Share Document